Leuject (Cladribine)

Cladribine is taken up by cells and phosphorylated to an active triphosphate that incorporates into DNA. This incorporation causes DNA strand breaks and triggers programmed cell death, especially in lymphocytes that have high activating enzyme activity, leading to selective depletion of these immune cells.

The dosing regimen for Leuject is determined by the prescribing clinician based on the specific indication, patient characteristics, and clinical guidelines. Healthcare professionals set the dose and schedule, and patients should follow the prescriber’s instructions without self‑adjustment.

Safety data for cladribine during pregnancy and lactation are limited. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk. Clinicians should discuss reproductive planning and contraception with patients before initiating therapy.

To order Leuject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Leuject (cladribine) is a purine nucleoside analog, whereas alternative disease‑modifying therapies for multiple sclerosis, such as alemtuzumab or ocrelizumab, are monoclonal antibodies. Cladribine offers a short‑course oral or injectable regimen with a distinct mechanism of selective lymphocyte depletion, while antibodies target surface antigens and often require continuous infusion.

Leuject should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures. Do not freeze. Follow any additional handling instructions provided by the supplier to maintain product integrity.

Leuject is administered by subcutaneous injection. A qualified healthcare professional prepares the dose according to the prescriber’s instructions and injects it into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique and proper disposal of sharps.

The most serious risks include severe infections due to immune suppression, opportunistic infections, and the rare development of secondary malignancies. Patients should be monitored for signs of infection, undergo regular blood counts, and report any unusual symptoms promptly to their healthcare provider.

Leuject is contraindicated in individuals with active, uncontrolled infections, known hypersensitivity to cladribine or any excipients, and those receiving live vaccines. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in pregnant or breastfeeding women unless absolutely necessary.